var data={"title":"Penicilloyl-polylysine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Penicilloyl-polylysine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5726?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=penicilloyl-polylysine-drug-information\" class=\"drug drug_general\">see &quot;Penicilloyl-polylysine: Drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140308\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Pre-Pen</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045544\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Diagnostic Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045538\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=penicilloyl-polylysine-drug-information\" class=\"drug drug_general\">see &quot;Penicilloyl-polylysine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Pediatric: <b>Diagnostic aid for detection of penicillin allergy (penicillin G and benzylpenicillin)</b>: Limited data available for assessment of other beta-lactams and cephalosporins allergy:Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Benzylpenicilloyl polylysine should always be applied first via the puncture technique. <b>Do not administer intradermally to patients who have positive reactions to a puncture test.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Puncture scratch test:</i> Apply a small drop of the skin test solution using a 22- to 28-gauge needle and make a single shallow puncture of the epidermis through the drop of solution. A positive reaction consists of a pale wheal surrounding the puncture site which develops within 10 minutes and ranges from 5 to 15 mm or more in diameter (wheal may be surrounded by erythema and variable degrees of itching). If a positive response is evident, the solution should be wiped off immediately. If the puncture test is negative or equivocal (&lt;5 mm wheal, with little or no erythema and no itching) 15 minutes following the puncture test, an intradermal test may be performed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Intradermal test:</i> Using a 0.5 to 1 mL tuberculin syringe with a <sup>3</sup>/<sub>8</sub>- to <sup>5</sup>/<sub>8</sub>-inch, 26- to 30-gauge short bevel needle; inject a volume of skin test solution sufficient to raise a small intradermal bleb ~3 mm in diameter intradermally and duplicate at least 2 cm apart. A control of 0.9% sodium chloride or allergen-diluting solution should be injected at least 5 cm from the antigen test site. Most skin responses to the intradermal test will develop within 5 to 15 minutes. A response to the skin test is read at 20 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Interpretation of intradermal test:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">(-) Negative: No increase in size of original bleb or no greater reaction compared to the control site.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">(&plusmn;) Ambiguous: Wheal only slightly larger than original bleb with or without erythematous flare and slightly larger than control site; <b>or</b> discordance between duplicate test sites.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">(+) Positive: Itching and marked increase in size of original bleb to &ge;5 mm. Wheal may exhibit pseudopods and be &gt;20 mm in diameter.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Control site should be reactionless. If wheal &gt;2 to 3 mm develops at control site, repeat the test. If same reaction occurs, consultation is necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140299\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, solution:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pre-Pen&reg;: 6 x 10<sup>-5</sup> M (0.25 mL) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140287\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045547\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Puncture test: Administer initially by puncture technique on the inner volar aspect of the forearm; observe 15 minutes for reaction. If negative reaction, follow with an intradermal injection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intradermal test: Do <b>not</b> administer intradermally to patients with a positive reaction to a puncture test (wheal of 5 to 15 mm or more in diameter). Administer the intradermal test on the upper, outer arm, below the deltoid muscle in the event a severe hypersensitivity reaction occurs and a tourniquet needs to be applied. During the skin test, immediate treatment with epinephrine should also be available. Observe 20 minutes for reaction.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2613412\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Refrigerate at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); discard if left at room temperature for longer than 1 day.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045546\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Adjunct in assessing the risk of administering penicillin (penicillin G or benzylpenicillin) in patients suspected of a clinical penicillin hypersensitivity (FDA approved in pediatric patients [age not specified] and adults). Has also been used as an adjunct in assessment of hypersensitivity to other beta-lactam antibiotics (penicillins and cephalosporins) to determine the safety of penicillin administration in patients with a history of reaction to cephalosporins</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140320\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Hypotension </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Erythema, pruritus, urticaria (including local reaction at skin test site) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Angioedema, hypersensitivity reaction (including anaphylaxis; rare)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Local inflammation (intense; at skin test site) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Dyspnea </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140304\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Systemic or marked local reaction to a previous administration of benzylpenicilloyl polylysine skin test; patients with a known severe hypersensitivity to penicillin should not be tested</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140291\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Allergic reactions: Rare systemic allergic reactions, including anaphylaxis, have been associated with penicillin skin testing. Penicillin skin testing should only be performed by skilled medical personnel under direct supervision of a physician, and testing should be performed only in an appropriate healthcare setting prepared for the immediate treatment with epinephrine. To decrease the risk of a systemic allergic reaction, the manufacturer recommends puncture skin testing prior to intradermal testing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Severe penicillin allergy: Patients with a reliable history of a severe life-threatening penicillin allergy, including Stevens-Johnson syndrome or TEN, should  <b>NOT</b> receive penicillin skin testing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Histamine H<sub>1</sub> antagonists: Responses to skin testing may be attenuated by concurrent administration of antihistamines. Consider delaying testing until these medications can be withheld to allow time for their effects dissipate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Accuracy: According to the manufacturer, a negative skin test is associated with an incidence of immediate allergic reactions of &lt;5% after penicillin administration and a positive skin test may indicate &gt;50% incidence of allergic reaction occurring after penicillin administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Adequate penicillin skin testing should ideally involve reagents of both the major antigenic determinant (penicilloyl-polylysine) and minor determinants (penicilloate or penilloate). Benzylpenicilloyl polylysine alone does not identify those patients who react to a minor antigenic determinant. The minor determinant mixture (MDM) is not commercially available in the U.S.; however, diluted penicillin G (concentration: 10,000 units/mL) has been used as a minor determinant for skin testing purposes (Bernstein, 2008). Penicillin skin testing does not predict the occurrence of late reactions (eg, type II, III, IV or idiopathic reactions).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298849\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140295\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=16454&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha-/Beta-Agonists: May diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.<b> Exceptions: </b>EPINEPHrine (Nasal); EPINEPHrine (Oral Inhalation); Isometheptene.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Agonists: May diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.<b> Exceptions: </b>Naphazoline (Nasal); Naphazoline (Ophthalmic); Oxymetazoline (Nasal); Phenylephrine (Nasal); Phenylephrine (Ophthalmic); Phenylephrine (Topical); Propylhexedrine; Xylometazoline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihistamines: May diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140297\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140306\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted with benzylpenicilloyl polylysine. The Centers for Disease Control and Prevention (CDC) states that penicillin skin testing may be useful in assessing suspected penicillin hypersensitivity in pregnant women diagnosed with syphilis (of any stage) due to a lack of proven alternatives to the use of penicillin in this population (CDC, 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12726989\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Observe 15 minutes (puncture) or 20 minutes (intradermal) for reaction.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140290\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Benzylpenicilloyl polylysine, a conjugate of the benzylpenicilloyl structural group (hapten) and the poly-l-lysine carrier (protein), is an antigen which reacts with  benzylpenicilloyl IgE antibodies to elicit the release of chemical mediators, thereby producing type I (immediate or accelerated) urticarial reactions in patients hypersensitive to penicillins.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045550\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Penicillin skin testing is the preferred method of evaluating patients with possible penicillin specific IgE-mediated (Type I) immediate hypersensitivity reactions, when performed using the appropriate major and minor determinant reagents. Testing detects the presence or absence of penicillin-specific IgE antibodies; therefore, it is not useful to detect non-IgE mediated reactions. Patients testing positive to benzylpenicilloyl polylysine possess IgE antibodies against the benzylpenicilloyl structural group (B-lactam ring). The possibility exists for patients to have selective IgE antibodies directed against the R-group side chain structure of certain penicillins, rather than the core beta-lactam structure. Therefore, these patients may test negative to the penicillin major and minor determinants, but be allergic to semisynthetic penicillins (eg, amoxicillin, ampicillin) only and tolerate other penicillin compounds (Bernstein 2008). Skin testing has also been used in some centers to determine safety of penicillin administration in patients with prior reactions to cephalosporins.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323015\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Pre-Pen Intradermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25 mL (0.25 mL): $116.40</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bernstein IL, Li JT, Bernstein DI, et al, &quot;Allergy Diagnostic Testing: An Updated Practice Parameter,&quot; <i>Ann Allergy Asthma Immunol</i>, 2008, 100(3 Suppl 3):1-148.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicilloyl-polylysine-pediatric-drug-information/abstract-text/18431959/pubmed\" target=\"_blank\" id=\"18431959\">18431959</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention, &ldquo;Sexually Transmitted Diseases Treatment Guidelines, 2006,&rdquo;<i> MMWR Recomm Rep</i>, 2009, 55(RR-11):1-94. Available at <a href=\"http://www.cdc.gov/std/treatment/2006/rr5511.pdf\" target=\"_blank\">http://www.cdc.gov/std/treatment/2006/rr5511.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pre-Pen (benzylpenicilloyl polylysine) [prescribing information]. Round Rock, TX: ALK-Abell&oacute;; April 2013.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16454 Version 42.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F140308\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1045544\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1045538\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F140299\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F140287\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1045547\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F2613412\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1045546\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F140320\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F140304\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F140291\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298849\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F140295\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F140297\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F140306\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F12726989\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F140290\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1045550\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323015\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/16454|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=penicilloyl-polylysine-drug-information\" class=\"drug drug_general\">Penicilloyl-polylysine: Drug information</a></li></ul></div></div>","javascript":null}